Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed its fiscal 2024 10-K annual report with the SEC on Mar 31, 2025.
- Top risk flagged: Regulatory risk: FDA may require additional clinical trials for QTORIN rapamycin, increasing development costs and delaying approvals
FY2024 key financial metrics · XBRL
- Net income
- −$17M
- +29.0% YoY
- EPS (diluted)
- −$7.83
- −460.8% YoY
- ROE
- -27.8%
- +63.9 pp YoY
- Operating cash flow
- −$11M
- +79.9% YoY
Source: XBRL data from the PALVELLA THERAPEUTICS, INC. (PVLA) FY2024 10-K on SEC EDGAR. USD.
PALVELLA THERAPEUTICS, INC. FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Risk Factors
- Regulatory risk: FDA may require additional clinical trials for QTORIN rapamycin, increasing development costs and delaying approvals
- Geopolitical risk: German R&D tax credit receivable of $2.0 million subject to changes in German tax laws and corporate reorganizations
- Operational risk: Reliance on CMOs for cGMP-compliant manufacturing and clinical supply creates vulnerability to supply chain disruptions
- Competitive risk: Competitors developing topical rapamycin products targeting the same rare genetic skin diseases indications
- Financial risk: $5.0 million milestone payment liability to Ligand under amended agreement possibly due before any commercialization revenue
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.